Logo

Top 20 Generics Pharma Companies Based On 2020 Revenue

Share this
Top 20 Generics Pharma Companies Based On 2020 Revenue

Vartika Singh

Top 20 Generics Pharma Companies Based On 2020 Revenue

  • Generic medicines are the backbone of the healthcare system and are identical to the innovator medicine in strength- effect- dosage form- and route of administration. These are allowed for sale after the patent expiry of the original drugs
  • Our team at PharmaShots has compiled a list of the top 20 generic companies based on their 2020 generic revenue
  • In the top 20 ledgers- Sandoz secured the top position with total revenue of $9.46B in the generic segment in 2020

Generic Segment Revenue: $0.22B

Founded Year: 1984 

Market Cap: $8.20B

Total Employees: 6-579

Headquarter: Mumbai- India

Stock Exchange: NSE

Piramal Healthcare is one of the leading pharmaceutical companies that deals with producing medicines in therapeutic areas such as diabetes- cardiovascular- inflammation and infectious diseases. In June 2020- Piramal sells 20% in pharmaceutical business to Carlyle for $490 million. Piramal Healthcare has generated revenue of $0.22B in 2020 from its generic segment.

Generic Segment Revenue: $0.31B

Founded Year: 1978

Market Cap: $5.40B

Total Employees: 12-609

Headquarter: Bengaluru- India

Stock Exchange: NSE

Biocon is an Indian Biopharmaceutical company that pivots its attention towards producing innovative drugs in areas such as oncology- immunotherapy and nephrology products. Biocon manufactures generic active pharmaceutical ingredients. In November 2020- Biocon planned a capex of $280 million for generic business over the next three years. In 2020- Biocon has generated revenue of $0.31B from its generic segment.

Generic Segment Revenue: $0.68B

Founded Year: 1867

Market Cap: $0.01B

Total Employees: 3-086

Headquarter: Surrey- United Kingdom

Stock Exchange: OTCMKTS

Mallinckrodt is an American-Irish pharmaceutical company. It targets on producing novel drugs in areas such as neurology- pulmonology- nephrology and rare diseases. In August 2020- Mallinckrodt announced US FDA filing acceptance of Biologics License Application for StrataGraft for the treatment of adults with thermal burns. In 2020- Mallinckrodt generated revenue of $0.68B from its generic segment.

Generic Segment Revenue: $0.78B

Founded Year: 1997

Market Cap: $1.02B

Total Employees: 3-397

Headquarter: Dublin- Ireland

Stock Exchange: NASDAQ

Endo International is a global pharmaceutical company that runs its business across a wide range of therapeutic areas including Endocrinology- Medical Aesthetics- Orthopaedics- and Urology & Men's Health. In December 2020- Endo completed acquisition of BioSpecifics. Endo has generated revenue of $0.78B from its generic segment in 2020.

Generic Segment Revenue: $1.09B

Founded Year: 1959

Market Cap: $6.29B

Total Employees: 13-801

Headquarter: Ahmedabad- India

Stock Exchange: NSE

Torrent is a leading pharmaceutical company and is ranked 8th in the Indian pharmaceutical market. It spotlights on developing novel therapies of Cardiovascular- central nervous system- gastro-intestinal- oncology- nephrology- anti-infective and pain management segments.?Torrent Pharma is ranked 11th among Indian companies operating in the US generic market. Torrent has generated business of $1.09B from its generic segment.  

Generic Segment Revenue: $1.13B

Founded Year: 1973

Market Cap: $125.95B

Total Employees: 99-412

Headquarter: Paris- France

Stock Exchange: EPA

Sanofi is a French multinational pharmaceutical company that covers 7 major therapeutic areas: cardiovascular- central nervous system- diabetes- internal medicine- oncology- thrombosis and vaccines. In September 2020- Sanofi completed Principia Biopharma Inc. Acquisition. In 2020- Sanofi has generated a sale of $1.13B from its generic segment.

Generic Segment Revenue: $1.34B

Founded Year: 2002

Market Cap: $1.67B

Total Employees: 6000

Headquarter: New Jersey- United States

Stock Exchange: NYSE

Amneal is an emerging pharmaceutical company that focuses across a broad range of therapeutic areas including cardiovascular- central nervous system- oncology- inflammation- anti-infective- dermatology- endocrinology- diabetes- and urology. In 2020- Amneal launched generic drugs Fluphenazine and Butrans. Amneal has generated a sale of $1.34B in 2020 from its generic segment.

Generic Segment Revenue: $1.49B

Founded Year: 1977

Market Cap: $1.84B

Total Employees: 14-000

Headquarter: Mumbai- India

Stock Exchange: NSE

Glenmark is an Indian pharmaceutical company that develops novel therapies for areas such as dermatology- respiratory- cardiology- diabetes- oncology and anti-infective. In June 2020- Glenmark became the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir- for the treatment of mild to moderate COVID-19. In December 2020- Glenmark became the first company to launch Remogliflozin and Vildagliptin fixed dose combination- at an affordable price for adults with Type 2 Diabetes in India. In 2020- Glenmark has generated a sale of $1.49B from its generic segment.

Generic Segment Revenue: $1.69B

Founded Year: 1929

Market Cap: $1.96B

Total Employees: 3003

Headquarter: Osaka- Japan

Stock Exchange: TYO

Sawai is a Japan based pharmaceutical company  associated with novel drug development in areas such as cardiovascular- diabetes drugs- anticancer drugs- and OTC drugs. In December 2020- Sawai launched two generic drugs with 10 strengths including Pregabalin and Rivastigmine. In 2020- Sawai has reported total sale of $1.69B from its generic segment.

Generic Segment Revenue: $2.01B

Founded Year: 1895

Market Cap: NA

Total Employees: 12-301

Headquarter: Bad Vilbel- Germany

Stock Exchange: NA

Stada is German based pharmaceutical company that mainly focuses on production of generic and over-the-counter drugs. In 2020- Stada acquired Lobsor Pharmaceuticals AB. Stada also acquired the product portfolio of Opti Pharm AG- a Swiss company specializing in the trade and distribution of pharmaceutical products. Stada has generated sales of $2.01B from its generic segment in 2020.

Generic Segment Revenue: $2.11B

Founded Year: 1984

Market Cap: $10.1B

Total Employees: 21-650

Headquarter: Hyderabad- India

Stock Exchange: NSE

Dr.Reddy is an Indian pharmaceutical company that targets on developing novel therapies in areas such as oncology- cardiovascular- diabetes- dermatology- nephrology and urology. In June 2020- Dr. Reddy?s Laboratories completed the acquisition of select business divisions of Wockhardt. In 2020- Dr.Reddy has recorded sales of $2.11B from its generic segment.

Generic Segment Revenue: $2.16B

Founded Year: 1968

Market Cap: $5.63B

Total Employees: 18-302

Headquarter: Mumbai- India

Stock Exchange: NSE

Lupin is an Indian pharmaceutical company that specifically focuses on developing novel drugs in therapeutic areas such as paediatrics- cardiovascular- anti-infectives- diabetology- asthma and anti-tuberculosis. In August 2020- Lupin received approval for generic Albuterol Sulphate MDI. In 2020- Lupin has generated sales of $2.16B from its generic segment.

Generic Segment Revenue: $2.34B

Founded Year: 1978

Market Cap: $7.71B

Total Employees: 8-600

Headquarter: London- United Kingdom

Stock Exchange: LON

Hikma is a British multinational pharmaceutical company that targets its business in key areas such as anti-infectives- cardiovascular- central nervous system- diabetes- oncology- respiratory. In March 2020- Hikma launched Everolimus tablets to expand its generics portfolio. In December 2020- Hikma also launched generic Advair Diskus. In 2020- Hikma has generated revenue of $2.34B from its generic segment.

Generic Segment Revenue: $2.61B

Founded Year: 1935

Market Cap: $9.60B

Total Employees: 25-845

Headquarter: Mumbai- India

Stock Exchange: NSE

Cipla is an Indian pharmaceutical company that develops novel drugs for areas such as respiratory- cardiovascular disease- arthritis- diabetes- weight control and depression. In 2020- Cipla received final approval for generic version of Migranal and Proventil. In 2020- Cipla has generated revenue of $2.61B from its generic segment.

Generic Segment Revenue: $3.38B

Founded Year: 1986

Market Cap: $5.31B

Total Employees: 18-469

Headquarter: Hyderabad- India

Stock Exchange: NSE

Aurobindo Pharma is an Indian pharmaceutical company that is specialised in manufacturing generic pharmaceuticals. Aurobindo focuses on key therapeutic areas including neurosciences- cardiovascular- anti-retrovirals- anti-diabetics- and gastroenterology. Aurobindo is among the top 10 pharmaceutical companies in India. In April 2020- Aurobindo received the final approval from l from the US Food and Drug Administration (USFDA) to manufacture and market Fluoxetine tablets in the strengths of 10 mg and 20 mg. In 2020- Aurobindo has generated sales of $3.38B from its generic segment.

Generic Segment Revenue: $3.58B

Founded Year: 1999

Market Cap: $26.12B

Total Employees: 311-269

Headquarter: Bad Homburg- Germany

Stock Exchange: ETR

Fresenius Kabi is a global healthcare company that focuses on multiple therapeutic areas including oncology- Generic & IV drugs- and Biosimilars- Infusion and Nutrition therapies. In October 2020- Fresenius Kabi launched Diprivan- the company first smart labelled product with Radio Frequency Identification (RFI). In 2020- Fresenius Kabi has generated sales of $3.58B from its generic segment.

Generic Segment Revenue: $4.52B

Founded Year: 1983

Market Cap: $25.89B

Total Employees: 36-000

Headquarter: Mumbai- India

Stock Exchange: NSE

Sun Pharma is an Indian pharmaceutical company that manufactures drugs in multiple therapeutic areas including cardiology- psychiatry- neurology- gastroenterology and diabetology. In August 2020- Sun Pharma launched FluGuard- which is used for the treatment of mild to moderate cases of Covid-19 in India. In 2020- Sun Pharma has generated revenue of $4.52B from its generic segment.

Generic Segment Revenue: $5.28B

Founded Year: 2020

Market Cap: $15.84B

Total Employees: 45-000

Headquarter: Pennsylvania- United States

Stock Exchange: NASDAQ

Viatris is a global healthcare company that specifically targets its business in therapeutic areas such as cardiovascular- oncology- immunology- CNS- infectious disease- gastroenterology- dermatology and respiratory for developing new drug therapies. In November 2020- Mylan merged with Upjohn- Pfizer's off-patent medicine division- to form Viatris. In 2020- Viatris has recorded sales of $5.28B from its generic segment.

Generic Segment Revenue: $9.31B

Founded Year: 1935

Market Cap: $10.77B

Total Employees: 37-736

Headquarter: Petah Tikva- Israel

Stock Exchange: NYSE

Teva is a global pharmaceutical company which is specialized in generic medicines. Teva is the world?s leading generic drug producer. In October 2020- Teva launched first generic versions of HIV-1 treatment Truvada and Atripla. In 2020- Teva has generated revenue of $9.31B from its generic segment.

Generic Segment Revenue: $9.46B

Founded Year: 2003

Market Cap: $208.86B

Total Employees: 26-500

Headquarter: Holzkirchen- Germany

Stock Exchange: NA

Sandoz is a leading pharmaceutical company that mainly focuses on generics and Biosimilars. ?The company is organized globally into three divisions Retail Generics- Anti-Infectives- and Biopharmaceuticals. In August 2020- Sandoz launched Ciprofloxacin and Dexamethasone otic suspension for the treatment of middle and outer ear canal bacterial infections. In 2020- Sandoz generated revenue of $9.46B from its generic segment.

  • For Viatris- only the biosimilar revenue was considered. Complex biosimilar and generics are not considered
  • In the annual report of Fresenius Kabi- the revenue was mentioned in percentage- so we calculated it as per the requirement
  • Source: Company annual reports- SEC filings- press releases- and company websites
  • Market Cap source: Google finance (as of 28th Oct 2021)
  • All revenues are reported in USD

Related Post: Top 20 Generics Pharma Companies Based On 2019 Revenue <

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family